Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity

Details Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity

2002-08-23

2008-08-05

Habte, Kahsay T (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S091000

Reexamination Certificate

active

07407954

ABSTRACT:
The use of a compound comprising formula (I), or a salt, ester, amide or prodrug thereof in the treatment of obesity and related disorders. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I): A is an optionally substituted thienyl moiety, Y is O, S, or NR2, R1is a branched or unbranched alkyl (optionally interrupted by one or more oxygen atoms), alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, reduced arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, reduced aryl, reduced heteroaryl, reduced heteroarylalkyl or a substituted derivative of any of the foregoing groups and R2is hydrogen or a group as defined for R1.

REFERENCES:
patent: 4598089 (1986-07-01), Hadvary et al.
patent: 4760063 (1988-07-01), Hallenbach et al.
patent: 0 129 748 (1985-01-01), None
patent: 0 908 457 (1999-04-01), None
patent: 0 985 670 (2000-03-01), None
patent: 2002-105081 (2002-04-01), None
patent: WO 00/30646 (2000-06-01), None
patent: WO 00/40247 (2000-07-01), None
patent: WO 00/40569 (2000-07-01), None
patent: WO 01/18181 (2001-03-01), None
patent: WO 01/53278 (2001-07-01), None
patent: WO 03/053944 (2003-07-01), None
Chalmers (TiPS vol. 17, pp. 166-172 Apr. 1996).
Thomas A. Godwin (Gastrointestinal Diseases, <http://edcenter.med.cornell.edu/CUMC—PathNotes/Gastrointestinal/Gastrointestinal.html>, 51 pages) downloaded on Aug. 11, 2004.
Gutschow et al. J. Med. Chem. 1998, 41, 1729-1740.
Wolff Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.So et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
Hu, Aixi, “Application Of Bioisosteric Principle In Drug Molecular Design.”,Hunan Chemical Industry2(4): 7-10, 1990. (Original in Chinese/ English Translation Enclosed).
Garin, et al., “Methyl N-Aryldithiocarbamates: Useful Reagents for the Annelation of Pyrimidines and 1,3-Oxazines to Five-Membered Heterocyclic Rings”,Heterocycles, 26(5): 1303-1312, 1987.
Gütschow, et al., “2-(Diethylamino) Thieno[1,3]Oxazin-4-Ones as Stable Inhibitors of Human Leukocyte Elastase”,J. Med. Chem. 42: 5437-5447, 1999.
Gütschow, et al., “Novel Thieno [2,3-d][1,3] Oxazin-4-Ones as Inhibitors of Human Leukocyte Elastase”,J. Med. Chem. 41: 1729-1740, 1998.
Krantz, et al., “Design and Synthesis of 4H-3,1-Benzoxazin-4-Ones as Potent Alternate Substrate Inhibitors of Human Leukocyte Elastase”,J. Med. Chem. 33: 464-479, 1990.
Pasquier, et al., “Viscous Soluble Dietary Fibers Alter Emulsification and Lipolysis of Triacylglycerols in Duodenal Medium in Vitro”,J. Nutr. Biochem. 7: 293-302, 1996.
Pietsch, et al., “Alternate Substrate Inhibition of Cholesterol Esterase by Thieno[2,3-d][1,3]Oxazin-4-Ones”,The Journal of Biological Chemistry, 277(27): 24006-24013, 2002.
Player, et al., “Preparation of Fused 1,3-Oxazine-2,4-Diones as Potential Antitumor Agents”,J. Heterocyclic Chem. 32: 1537-1540, 1995.
Wang, et al., “A New Approach to the Synthesis of Heteroannulated 3,1-Oxazin-4-Ones from β-Enamino Esters and Phosgeneiminium Salts”,Synthesis, 2: 255-258, 2000.

Affiliated with

Also associated with

Rating

Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4017459